Potential biomarkers for the diagnosis of respiratory tract infection and lungs cancer.
Potential biomarkers for the diagnosis of respiratory tract infection and lungs cancer. Cell Mol Biol (Noisy-le-grand). 2017 Nov 30;63(11):46-52 Authors: Khan K, Aslam MA, Zahra FT, Basheer H, Bilal M, Sumrin A Abstract Major hurdle faced by many physicians in treating various respiratory tract infections and lung carcinomas is their late or mis-diagnosis. In most respiratory tract infections the manner of infection is not completely understood. Similarly, various lung carcinomas are diagnosed at advance stages at which not only the treatment possibilities are narrowed but the chances of survival are also reduced. So, for the sake of better treatment, the quick and improved diagnostic strategies are suggested. Protein biomarkers fully fit the description in this regard as they have shown great potential in specific diagnosis of many respiratory diseases and also have shown capability in timely pin pointing different stages of lung carcinomas. Many serum biomarkers are presently being used for diagnosis but the efficiency for diagnosis of these biomarkers is lower when used alone. So, physicians are suggested to use the combination of different biomarkers. Moreover, genetic biomarkers are also currently studied to indicate the exact stage of disease, the possible damage occurred, the severity of disease and also for the analysis of the possible body response to the therapeutics. PMID: 29208181 [PubMed - in process]
Conclusions: This study suggests a clinical benefit of EP related to improved toxicity management of sorafenib that resulted in fewer dose reductions. Implications for Practice: Patients treated with sorafenib may benefit from an EP. Different types of EP should be compared prospectively, focusing on patients’ quality of life.
Several treatment options exist for keratinocyte carcinomas (KCs), such as electrodessication and curettage (EDC), excision, and Mohs surgery (MS). We hypothesized that in an older population treatment utilization would vary by age. Using the Medicare Current Beneficiary Survey from 2001-2010, KCs identified by ICD-9, treatments identified by CPT, and multinomial logistic regression accounting for clustering, we compared KC treatments by gender, race, history of skin cancer, KC location and type, age, comorbidities, functional status, and predicted mortality (Lee Index).
Uncontrolled Hedgehog (Hh) signaling underlies the development of basal cell carcinoma (BCC), with superficial BCCs arising from interfollicular epidermis and nodular tumors from hair follicle epithelia. However, the precise cell populations that give rise to different BCC subtypes have not been fully defined. Moreover, although genetic or pharmacological shut-down of oncogenic Hh signaling in BCC leaves behind a small population of dormant tumor cells, the long-term fate of these cells has not been investigated.
Conclusions: K19-proficient HCC exhibited poor prognosis owing to extrahepatic recurrence, with molecular signatures differing from those in conventional cancer stem cells, providing novel insights of the heterogeneity underlying tumor development.Liver Cancer
The American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, presented exciting updates in urothelial carcinoma. Here, Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center,... Author: VJOncology Added: 08/21/2018
Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, reviews treatment options for bladder cancer. She highlights how MVAC is still used today, with clinical trials failing to ide... Author: VJOncology Added: 08/21/2018
Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the first results of the primary analysis of the Phase II BLC2001 study (NCT02365597) of erdafitinib in patients wit... Author: VJOncology Added: 08/21/2018
Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, reviews treatment options for bladder cancer. She highlights how MVAC is still used today, with clinical trials failing to ide... Author: VJHemOnc Added: 08/21/2018
Anaplastic thyroid carcinomas (ATCs) have a high prevalence of BRAF and TP53 mutations. A trial of vemurafenib in nonmelanoma BRAFV600E-mutant cancers showed significant, although short-lived, responses in ATCs, indicating that these virulent tumors remain addicted to BRAF despite their high mutation burden. To explore the mechanisms mediating acquired resistance to BRAF blockade, we generated mice with thyroid-specific deletion of p53 and dox-dependent expression of BRAFV600E, 50% of which developed ATCs after dox treatment. Upon dox withdrawal there was complete regression in all mice, although recurrences were later det...
ConclusionThe dual specificity of VGB for VEGFR1 and VEGFR2, through which the PI3K/AKT and MAPK/ERK1/2 signaling pathways can be abrogated and, subsequently, angiogenesis, tumor growth, and metastasis are inhibited.General significance.This study demonstrated that simultaneous blockade of VEGFR1 and VEGFR2 downstream cascades is an effective means for treatment of various angiogenic disorders, especially cancer.